Cipla announces a new respiratory inhaler: Synchrobreathe (SB), a state-of-the-art breath-actuated inhaler which will bring relief to millions of patients with Obstructive Airway Disease (OAD, asthma and COPD)
Cipla announces an investment led by Fidelity Growth Partners India into the newly launched Consumer Healthcare business
Cipla Board Announces Appointment of Samina Vaziralli onto the Board of Directors
Stempeutics receives Japan process patent for its novel stem cell drug “Stempeucel®”
Cipla Announces US FDA Approval for the World’s First Paediatric Lopinavir and ritonavir Oral Pellets for the Treatment of AIDS in Infants and Young Children
Stempeutics receives Orphan Drug Designation (ODD) in the European Union for its novel stem cell drug “Stempeucel®” for the treatment of Thromboangiitis Obliterans
